Translational PK/PD for the Development of Novel Antibiotics-A Drug Developer's Perspective

• Príomhchruthaitheoirí: Caterina Bissantz (Údar), Claudia Zampaloni (Údar), Pascale David-Pierson (Údar), Guennaelle Dieppois (Údar), Andreas Guenther (Údar), Andrej Trauner (Údar), Lotte Winther (Údar), William Stubbings (Údar)
• Formáid: LEABHAR
• Foilsithe / Cruthaithe: MDPI AG, 2024-01-01T00:00:00Z.
• Ábhair: article
• Rochtain ar líne: Connect to this object online.

Antibiotic development traditionally involved large Phase 3 programs, preceded by Phase 2 studies. Recognizing the high unmet medical need for new antibiotics and, in some cases, challenges to conducting large clinical trials, regulators created a streamlined clinical development pathway in which a...